학술논문
Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study
Document Type
Article
Author
Source
In The Lancet HIV January 2017 4(1):e13-e20
Subject
Language
ISSN
2352-3018